Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health Reform Roundup: A Week Of Ups And Downs For Democratic Effort

This article was originally published in The Gray Sheet

Executive Summary

Three of the five involved committees in Congress approved comprehensive health care reform legislation last week, but it was still a week laden with barriers and delays to the overall goal of getting legislation to the president's desk

You may also be interested in...



Finance Dems Block Move To Strip Device Fee, But Signal Room To Negotiate

An amendment that would have stripped a proposed $4 billion annual fee on device manufacturers from health care reform legislation was voted down by Senate Finance Committee Democrats Oct. 1, but they signaled an interest to negotiate further

Finance Dems Block Move To Strip Device Fee, But Signal Room To Negotiate

An amendment that would have stripped a proposed $4 billion annual fee on device manufacturers from health care reform legislation was voted down by Senate Finance Committee Democrats Oct. 1, but they signaled an interest to negotiate further

Harkin At HELP's Helm: Industry Sees Senator's Prevention Focus As Positive

Incoming Senate HELP Committee Chairman Tom Harkin brings a longstanding interest in preventive medicine, a topic that has also been emphasized by the device industry as part of the ongoing health reform debate

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel